A company developing a technology to edit genes at the single-letter level has filed to go public.
In an S-1 filing with the Securities and Exchange Commission Friday, Cambridge, Massachusetts-based Beam Therapeutics announced its planned $100 million initial public offering on the Nasdaq Global Market, where it would trade under the symbol BEAM. JP Morgan, Jefferies and Barclays are joint bookrunners on the IPO, while Wedbush PacGrow is lead manager.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The company declined to comment because it is in a quiet period in connection with the filing.
Beam’s last major financing was a $135 million Series B funding round that it raised in March. It launched in May of last year with an $87 million Series A round after operating in stealth mode for a year. Venture capital firms ARCH Venture Partners and F-Prime Capital Partners led the Series A round.
The company is developing “base editing” technology designed to enable editing of the genome at the single-letter level, as opposed to the “cutting” of DNA and RNA usually involved in CRISPR/Cas9 gene editing. Each letter of the genome corresponds with a specific nucleobase: A for adenine, G for guanine, T for thymine and C for cytosine. Base editing would enable changing C to T, G to A and so forth.
In April, the company presented data the American Society of Gene and Cell Therapy’s annual meeting in Washington on multiplex base editing for its engineered CAR-T cells. In the preclinical study, the company used the base editor BE4 to edit three different cell-surface targets on primary human T cells, namely the proteins TRAC, B2M and PD-1. It was able to knock out expression of each gene in 95 percent, 95 percent and 88 percent of cells, respectively, using electroporation.
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Beam has been licensing technology from multiple firms and academic institutions. At the time of its launch last May, it had licensing agreements with the Massachusetts Institute of Technology and Harvard University’s Broad Institute for CRISPR/Cas9 pioneer Feng Zhang’s RNA base editing technology and with Editas Medicine for technologies it developed and licensed from Harvard, the Broad and Massachusetts General Hospital. In May of this year, it in-licensed intellectual property for base editing in human therapeutics from Bio Palette, a company based in Kobe, Japan.
Photo: jxfzsy, Getty Images